Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic oncology products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

01/03/2026

Join Telix for an educational investor webinar, ‘The Future of Prostate Imaging: What do physicians want?’

Hear directly from clinicians on how PSMA-PET/CT is being used in practice, how the field is evolving and what physicians want next from prostate cancer imaging - alongside Telix perspectives on how the Company is meeting these needs.

Speakers
🔵Rod Hicks, MD - Melbourne Theranostic Innovation Centre
🔵Paul Yonover, MD, FACS - UroPartners, Chicago
🔵Darren Patti, PharmD - Telix

Learn more and register here: https://bit.ly/4kZHo1c

This Kidney Cancer Awareness Month, we’re turning orange to highlight the impact this disease has on more than 400,000 p...
01/03/2026

This Kidney Cancer Awareness Month, we’re turning orange to highlight the impact this disease has on more than 400,000 people globally each year.

At Telix, our focus is delivering precision care across the patient journey.

We are advancing targeted therapeutics designed to more effectively treat kidney cancer alongside precision medicine imaging agents to non-invasively find disease. Through this theranostic approach, we aim to support more personalized treatment for patients and more confident clinical decision making.

See it. Treat it.

U.S. patients and physicians can learn more about how we’re advancing kidney cancer detection and management at SeeccRCC.com

Learn more about the Telix kidney cancer portfolio: telixpharma.com/kidney

Telix announces a research collaboration with University Hospital Essen on the PROMISE-PET registry, defining the potent...
28/02/2026

Telix announces a research collaboration with University Hospital Essen on the PROMISE-PET registry, defining the potential prognostic value of PSMA-PET imaging through AI.

The registry has been collecting and analyzing patient data since 2018 with PET readings from more than 15,000 patients standardized using the PROMISE framework. The aim of this new collaboration with Telix is to develop and validate AI-based prediction models for survival, and compare performance with established clinically prognostic nomograms.

Working together with leading investigators and having access to one of the world’s largest PSMA-PET datasets has potential to inform future guideline recommendations and clinical decision making.

Read more on our website here: https://telixpharma.com/news-views/telix-joins-forces-with-university-hospital-essen-on-promise-pet-optimizing-patient-management-through-ai-enabled-psma-pet-imaging/

19/02/2026

Telix announces full year results and releases its Annual Report for the year ending December 31, 2025.

During 2025, Telix delivered strong commercial growth, with Group revenue increasing to US$804 million (+56% compared with FY 2024) and achieving upsized full year guidance.

Telix Precision Medicine revenue increased 22% year-over-year, driven by continued increase in Illuccix® volumes and the successful U.S. launch of Gozellix®, with segment EBITDA increasing by 24% to $216M.

The strong commercial performance has enabled Telix to fund investment into our late-stage pipeline and best-in-class commercial team, paving the way for future growth opportunities.

Telix will hold an investor webcast at 9:30 a.m. AEDT this morning, Friday, February 20, 2026 (5:30 p.m. EST, Thursday, February 19) to present results and an operational update.

To view Telix’s 2025 Annual Report and for details on the investor webcast visit our website: https://telixpharma.com/news-views/fy-2025-results-strong-commercial-growth-focused-pipeline-investment/

Telix has submitted a European Marketing Authorization Application (MAA) for TLX101-Px (¹⁸F-FET), our investigational PE...
17/02/2026

Telix has submitted a European Marketing Authorization Application (MAA) for TLX101-Px (¹⁸F-FET), our investigational PET imaging agent for glioma.

Across Europe, amino-acid PET imaging is used in clinical practice, however, there is currently no generally available commercial product. With TLX101-Px, Telix aims to expand access to advanced imaging and support more confident and timely management of patients with brain tumors.

Telix has been preparing the European and U.S. regulatory packages in parallel, bringing forward the European submission to meet an agreed filing timeline while aligning with aspects of the FDA resubmission, which will follow.

Read more on our website here: https://telixpharma.com/news-views/telix-submits-european-marketing-authorization-application-for-tlx101-px-for-brain-cancer-imaging

TLX101-Px has not received a marketing authorization in any jurisdiction.

Wishing our collaborators, colleagues and friends a safe and prosperous Lunar New Year.Across Asia, including Greater Ch...
17/02/2026

Wishing our collaborators, colleagues and friends a safe and prosperous Lunar New Year.

Across Asia, including Greater China, Telix is partnering to expand access to targeted radiopharmaceuticals. Recent progress includes:

🔴 Acceptance of the New Drug Application in China for TLX591-Px (Illuccix®*) prostate cancer imaging

🔴 Approval for the ProstACT Global trial of TLX591-Tx in metastatic castration-resistant prostate cancer to commence in China, Singapore and South Korea, and

🔴 Publication of final results from the ZIRDOSE-CP Phase 1 study of TLX250-Px (Zircaix®*) PET imaging in Chinese patients with suspected clear cell renal cell carcinoma.

We look forward to continuing this momentum and working together to help patients with cancer and rare diseases across the region live longer, better quality lives.

TLX591-Px, TLX250-Px and TLX591-Tx have not received marketing authorization China. *Brand names subject to final regulatory approval.

04/02/2026

This World Cancer Day, we’re reminded that every cancer journey is unique.

Behind every diagnosis, every scan, every treatment, there is a patient, a family, and a community holding onto hope. Hope for answers. Hope for options. Hope for what comes next.

At Telix, that shared hope is what inspires us every day.

Through innovation and collaboration, we are striving to bridge gaps in care, empower patients through personalized treatment, and support healthcare teams on the front lines.

To learn more about World Cancer Day visit: www.worldcancerday.org

Telix will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT.An invest...
03/02/2026

Telix will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT.

An investor webcast will be held at 9:30 a.m. AEDT (5:30 p.m. EST, Thursday 19 February).

To register for the webcast visit: https://edge.media-server.com/mmc/p/famdpwzh

Telix provides an update on its commercial and operational performance for Q4 2025.The Company delivered full-year reven...
20/01/2026

Telix provides an update on its commercial and operational performance for Q4 2025.

The Company delivered full-year revenue of US$804M (A$1.2B), achieving upgraded guidance.

The Precision Medicine business delivered excellent sequential growth in the quarter, driven in part by the successful U.S. launch of Gozellix, following CMS reimbursement.

Telix continues to advance multiple late-stage therapeutic programs, with first patients dosed in the SOLACE Phase 1 study for TLX090-Tx in metastatic bone pain and Part 2 of the ProstACT® Global Phase 3 study of TLX591-Tx .

For more on our Q4 2025 results, visit: https://telixpharma.com/news-views/telix-achieves-fy-2025-guidance-with-us804m-a1-2b-revenue-accelerates-growth-with-gozellix-launch/

TLX591-Tx and TLX090-Tx have not received marketing authorizations in any jurisdiction.

Join Telix this week at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading internati...
01/12/2025

Join Telix this week at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading international congresses dedicated to advances in urologic cancer care, being held in Phoenix (AZ).

Telix will showcase 3 of the Phase 3 studies from its urology development program, including:

🔵 ProstACT Global, Telix’s lead prostate cancer therapy candidate, TLX591, in metastatic castration-resistant prostate cancer;

🔵 BiPASS, ⁶⁸Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer; and

🔵 ZIRCON-X, evaluating the impact of Telix’s kidney cancer imaging candidate, TLX250-CDx, on clinical decision-making in patients with indeterminate renal masses.

Swipe the carousel to explore presentations and session times.

Follow the link to learn more: https://telixpharma.com/telix-at-suo-2025/

TLX250-CDx and TLX591 have not received a marketing authorization in any jurisdiction.

Telix has officially opened Telix Manufacturing Solutions (TMS) in Yokohama, Japan, our first cyclotron facility in the ...
24/11/2025

Telix has officially opened Telix Manufacturing Solutions (TMS) in Yokohama, Japan, our first cyclotron facility in the Asia Pacific region.

The opening was commemorated with a lecture delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association, on “Trends and Challenges for the Future of Nuclear Medicine.”

The site will initially support clinical supply of TLX250-CDx in the region for kidney cancer imaging, with plans to expand to additional investigational and future commercial products, subject to regulatory approval.

Read more here: https://bit.ly/49EmHUX

TLX250-CDx has not received a marketing authorization in any jurisdiction.

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Telix Pharmaceuticals Limited:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Telix Pharmaceuticals Limited was established in January 2017. We are a clinical-stage biotechnology company developing a pipeline of molecularly-targeted radiation (MTR) therapies to image and treat cancer. Our team is an experienced group of biopharma clinicians and executives, with a passion for radiation biology and oncology.

In December 2018, Telix acquired ANMI SA, a leader in the field of radiopharmaceutical development. The ANMI team brings a wealth of innovation and experience in the streamlined development and production of novel radiopharmaceuticals. For more information about ANMI, visit anmi.be.

Our products currently focus on unmet needs in cancer care, specifically in:


  • Prostate